Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.750
+0.030 (1.74%)
At close: Jun 26, 2026, 4:00 PM EDT
1.760
+0.010 (0.57%)
After-hours: Jun 26, 2026, 7:43 PM EDT
Gain Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Gain Therapeutics stock have an average target of 7.20, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 311.43% from the current stock price of 1.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Gain Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +357.14% | Jun 8, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $8 | Buy | Reiterates | $8 | +357.14% | May 27, 2026 |
| BTIG | BTIG | Buy Maintains $5 | Buy | Maintains | $5 | +185.71% | May 26, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $7 | Buy | Maintains | $7 | +300.00% | May 14, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Reiterates $8 | Buy | Reiterates | $8 | +357.14% | May 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.60
from -0.61
EPS Next Year
-0.60
from -0.60
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.60 | -0.60 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.